Using our computational platforms, we have discovered novel potential targets for antibody drug conjugate (ADC) cancer therapy. For two of these we have disclosed positive initial experimental results. These two candidates demonstrated low expression levels in normal critical tissues, such as heart and liver and higher expression in multiple cancer types, including colorectal, pancreatic, and prostate cancers, for which there is high unmet medical need. The two are now at the stage of therapeutic antibody discovery. The rest of the ADC target candidates are currently at the validation stage and have the potential to address additional cancer indications and patient populations, demonstrating a broad and diversified portfolio for this promising mode of therapy.